Inlyta (axitinib) — United Healthcare
follicular carcinoma
Initial criteria
- Diagnosis of follicular carcinoma OR oncocytic carcinoma OR papillary carcinoma
- Disease is recurrent and unresectable OR persistent OR metastatic
- Not amenable to radioactive iodine (RAI) treatment
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inlyta therapy
Approval duration
12 months